The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis

Svedbom, Axel; Dalén, Johan; Ivergård, M; Borse, Rebekah H.; Black, Christopher M.; Luttropp, Karin; Kachroo, Sumesh

doi:10.1007/s10198-019-01110-w

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies have shown that among biologic‐naïve patients who start treatment with a subcutaneous TNFi for immune‐mediated rheumatic diseases, healthcare resource utilisation is greater among those who switch or discontinue therapy compared with those who persist with their first‐line treatment (Carballo et al., 2021; Dalén et al., 2020). Thus, there is evidence that prescribing a TNFi with the greatest probability of persistence may be a cost‐effective strategy (Svedbom et al., 2020).…”

Section: Discussionmentioning

confidence: 99%

Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

Pombo‐Suárez

Seoane‐Mato

Dı́az-González

et al. 2022

Musculoskeletal Care

View full text Add to dashboard Cite

Aim:To assess the golimumab retention rate during up to 8 years of follow up, and any associated factors.Methods: Retrospective analysis of the BIOBADASER (Spanish registry of biological drugs) database, assessing all adults who had ever started golimumab >6 months before the analysis for an approved indication (rheumatoid arthritis [RA], axial spondyloarthritis [SpA] or psoriatic arthritis [PsA]).Results: Among 885 patients (RA 267, axial SpA 370, PsA 248) receiving 944 cycles of golimumab, the retention rate of golimumab was 71.1% (95% confidence interval:This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

show abstract

Section: Discussionmentioning

confidence: 99%